Skip to main content
Monthly Archives

January 2026

AMA to Congress: Make Medicare Telehealth Services Permanent

By News

By Marissa Plescia (MedCityNews.com)

In an issue brief released Monday, the American Medical Association (AMA) urged Congress to make permanent the Medicare telehealth flexibilities introduced during the Covid-19 pandemic.

Before Covid-19, only a select few Medicare beneficiaries could access virtual care. They had to be in a rural setting, not an urban or suburban setting. They also could only use telehealth in an approved originating site, like a hospital or a physician’s office. These restrictions were waived during Covid-19 in order to expand access to care.

These flexibilities have been extended numerous times and are currently set to expire at the end of January. This reliance on temporary extensions has created uncertainty for providers and patients, the AMA argued in the issue brief.

“Since the Covid-19 public health emergency, Congress has repeatedly extended telehealth flexibilities for Medicare patients—often at the last moment—creating uncertainty for millions of patients and their physicians,” said AMA President Dr. Bobby Mukkamala, in a statement. “As the current waiver deadline approaches, Congress must finally act decisively to prevent a disruptive and abrupt halt to the expanded telehealth services that have improved care continuity, chronic disease management, and access for rural and underserved communities.”

The issue brief explains that telehealth use surged during the pandemic, with more than 28 million Medicare beneficiaries using virtual care, and studies show telehealth visits are 9.2 percentage points more likely to be completed than in-person appointments.

In addition, multiple studies, including one from the University of Michigan, found that telehealth does not increase overall utilization and can lower costs, with one study showing $82 lower Medicare spending per patient after a telehealth visit compared with in-person care.

The AMA calls for several congressional actions, including permanently removing restrictions on Medicare coverage of telehealth services so patients can receive telehealth at home regardless of location. The organization also asks to extend the Acute Hospital at Home Care waiver through 2030 and authorize continued use of virtual diabetes prevention programs. It is also pushing lawmakers to address coverage and payment barriers for remote patient monitoring devices to improve maternal and child health outcomes under Medicaid.

“When thoughtfully integrated, particularly through coordinated systems and hybrid care models, telehealth has demonstrated the ability to reduce care fragmentation, improve outcomes, enhance patient engagement and lower costs,” the AMA stated in the issue brief. “Real-world data increasingly supports its role in delivering high-quality, efficient care across populations. Yet many telehealth flexibilities remain tethered to temporary pandemic-era policies. Treating them as stopgap measures rather than foundational tools undermines progress toward a modern, innovative and resilient health system.”

DEA Extends Telemedicine Flexibilities to Ensure Continued Access to Care

By News

WASHINGTON – The U.S. Drug Enforcement Administration, in partnership with the Department of Health and Human Services (HHS), has issued a Fourth Temporary Extension of the COVID-19 Telemedicine Flexibilities for the Prescription of Controlled Medications, extending the current telemedicine flexibilities through December 31, 2026.

Under these telemedicine flexibilities, DEA-registered practitioners are permitted to remotely prescribe Schedule II-V controlled medications via audio-video telemedicine encounters, including Schedule III-V narcotic controlled medications approved by the Food and Drug Administration (FDA) for maintenance and withdrawal management treatment of opioid use disorder via audio-only telemedicine encounters, without having ever conducted an in-person medical evaluation, provided that such prescriptions otherwise comply with the requirements outlined in DEA guidance documents, DEA regulations, and applicable federal and state law.

“DEA supports telehealth access for patients who need medication, but not at the expense of public safety,” said DEA Assistant Administrator Cheri Oz, Diversion Control Division. “These rules aim to protect patients, expand access to care, and close the door on diversion into the illicit drug market.”

DEA recognizes that the expiration of the current telemedicine flexibilities without further regulation could disrupt patient care. This extension provides critical benefits, including:

  • Ensuring continuity of care for patients who rely on telemedicine, particularly those in rural and underserved areas, the elderly, and patients with mobility limitations
  • Preventing a backlog of patients needing in-person appointments
  • Allowing time to finalize and implement regulations that balance access to care with the necessary safeguards against drug diversion

On January 17, 2025, DEA and HHS published two final rules titled Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients (collectively referred to as the “Two Final Rules”). These rules take effect December 31, 2025.

The Fourth Temporary Extension, along with the Two Final Rules, provides three distinct sets of authorities for telemedicine prescribing, each with unique requirements. Practitioners covered by one or both of the Two Final Rules may continue to utilize the telemedicine flexibilities under the fourth temporary rule, which imposes fewer requirements than the Two Final Rules.

For more informationFederal Register :: Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications.

 

Information provided in a press release from the United States Drug Enforcement Administration.